Acalabrutinib ± obinutuzumab demonstrates durable disease control and tolerability in treatment-naïve CLL

In this MEDtalk Talha Munir, MD, Consultant Haematologist, St James’s Hospital, Leeds, UK, presents the five-years updated analysis of the phase III ELRVATE-TN trial. In this trial, treatment-naïve patients with CLL are treated with acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil. As indicated, the study demonstrates durable disease control and tolerability.